References:
1. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev
Dis Prim . 2018;4:18010. doi:10.1038/nrdp.2018.10
2. Famodu AA, Oduwa D. Platelet count and platelet factor 3 (PF-3)
availability in sickle cell disease. Br J Biomed Sci .
1995;52(4):323-324.
3. Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell
disease: a consequence of hyposplenism. J Clin Pathol .
1980;33(7):622-625. doi:10.1136/jcp.33.7.622
4. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a
curious paradox. Am J Med . 2003;115(9):721-728.
doi:10.1016/j.amjmed.2003.07.011
5. Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid
antibodies, proteins C and S, and coagulation changes in sickle cell
disease. J Lab Clin Med . 1999;134(4):352-362.
doi:10.1016/s0022-2143(99)90149-x
6. Ataga KI. Hypercoagulability and thrombotic complications in
hemolytic anemias. Haematologica . 2009;94(11):1481-1484.
doi:10.3324/haematol.2009.013672
7. Srisuwananukorn A, Raslan R, Zhang X, et al. Clinical, laboratory,
and genetic risk factors for thrombosis in sickle cell disease.Blood Adv . 2020;4(9):1978-1986.
doi:10.1182/bloodadvances.2019001384
8. Scarpato B, Strykowski R, Lawrence R, et al. Risk factors for Venous
Thromboembolism and clinical outcomes in adults with sickle cell
disease. Thromb Updat . 2022;6. doi:10.1016/j.tru.2022.100101
9. Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous
thromboembolism in adults with sickle cell disease: a serious and
under-recognized complication. Am J Med . 2013;126(5):443-449.
doi:10.1016/j.amjmed.2012.12.016
10. Brunson A, Keegan T, Mahajan A, White R, Wun T. High incidence of
venous thromboembolism recurrence in patients with sickle cell disease.Am J Hematol . 2019;94(8):862-870. doi:10.1002/ajh.25508
11. O’Brien SH, Stanek JR, Witmer CM, Raffini L. The Continued Rise of
Venous Thromboembolism Across US Children’s Hospitals.Pediatrics . 2022;149(3). doi:10.1542/peds.2021-054649
12. Betensky M, Kumar R, Hankins JS, Goldenberg NA. Venous
thromboembolism in pediatric patients with sickle cell disease: A north
American survey on experience and management approaches of pediatric
hematologists. Thromb Res . 2022;211:133-139.
doi:10.1016/j.thromres.2022.01.028
13. Children’s Hospitals’ Solutions for Patient Safety. SPS VTE
prevention bundles.
14. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric
thromboembolic disease: a report from the Canadian Childhood
Thrombophilia Registry. Pediatr Res . 2000;47(6):763-766.
doi:10.1203/00006450-200006000-00013
15. Humes DJ, Nordenskjöld A, Walker AJ, West J, Ludvigsson JF. Risk of
venous thromboembolism in children after general surgery. J
Pediatr Surg . 2015;50(11):1870-1873. doi:10.1016/j.jpedsurg.2015.05.010
16. Manlhiot C, Brandão LR, Schwartz SM, et al. Management and Outcomes
of Patients with Occlusive Thrombosis after Pediatric Cardiac Surgery.J Pediatr . 2016;169:146-153. doi:10.1016/j.jpeds.2015.10.046
17. Schulman S, Angerås U, Bergqvist D, et al. Definition of major
bleeding in clinical investigations of antihemostatic medicinal products
in surgical patients. J Thromb Haemost . 2010;8(1):202-204.
doi:10.1111/j.1538-7836.2009.03678.x
18. Sharma R, Woods GM, Creary S, et al. Impact of erythrocytapheresis
on natural anticoagulant levels in children with sickle cell disease: A
pilot study. Pediatr Blood Cancer . 2019;66(4):e27588.
doi:10.1002/pbc.27588
19. Kumar R, Stanek J, Creary S, Dunn A, O’Brien SH. Prevalence and risk
factors for venous thromboembolism in children with sickle cell disease:
An administrative database study. Blood Adv . 2018;2(3):285-291.
doi:10.1182/bloodadvances.2017012336
20. Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in
venous thromboembolism in children’s hospitals in the United States from
2001 to 2007. Pediatrics . 2009;124(4):1001-1008.
doi:10.1542/peds.2009-0768
21. Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni M V. Pulmonary
embolism in sickle cell disease: a case-control study. J Thromb
Haemost . 2012;10(5):760-766. doi:10.1111/j.1538-7836.2012.04697.x
22. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk
of venous thromboembolism among blacks. Blood .
2007;110(3):908-912. doi:10.1182/blood-2006-11-057604
23. Mekontso Dessap A, Deux J-F, Abidi N, et al. Pulmonary artery
thrombosis during acute chest syndrome in sickle cell disease. Am
J Respir Crit Care Med . 2011;184(9):1022-1029.
doi:10.1164/rccm.201105-0783OC
24. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous
thromboembolism: What the anticoagulation expert needs to know. In:Journal of Thrombosis and Thrombolysis . Vol 35. ; 2013:352-358.
doi:10.1007/s11239-013-0895-y
25. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of
the acute chest syndrome in sickle cell disease. National Acute Chest
Syndrome Study Group. N Engl J Med . 2000;342(25):1855-1865.
doi:10.1056/NEJM200006223422502
26. Mahajerin A, Croteau SE. Epidemiology and risk assessment of
pediatric venous thromboembolism. Front Pediatr .
2017;5(April):1-7. doi:10.3389/fped.2017.00068
27. Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B. Long-term central
venous access in patients with sickle cell disease. Incidence of
thrombotic and infectious complications. J Pediatr Hematol Oncol .
1995;17(4):342-345. doi:10.1097/00043426-199511000-00011
28. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial
thromboembolic complications in COVID-19 patients admitted to an
academic hospital in Milan, Italy. Thromb Res . 2020;191:9-14.
doi:10.1016/j.thromres.2020.04.024
29. Liem RI, Lanzkron S, Coates TD, et al. American Society of
Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and
kidney disease. Blood Adv . 2019;3(23):3867-3897.
doi:10.1182/bloodadvances.2019000916